1 in 8 Cancers Starts as an Infection. A Significant Share Is Preventable — We Are Just Not Acting.

One in eight. That's the share of all new cancers diagnosed worldwide in 2024 that a virus, bacterium, or parasite set in motion. Not bad genes. Not bad luck. Infections — for which we already have vaccines, antibiotics, and screening tests sitting on shelves.

That's the headline finding of a new analysis from the International Agency for Research on Cancer (IARC), the World Health Organization's cancer arm, published in The Lancet Oncology. The team counted roughly 2.3 million infection-driven cancer cases in a single year, across 12 infectious agents the agency classifies as definite human carcinogens. And the study's authors put it plainly: a significant share of this burden is preventable through better infection control.

2.3 million cases is not a rounding error

Twelve percent sounds small until you put a frame on it. Dr. Patrick Moore, chair of Innovative Cancer Research at the University of Pittsburgh, compared it to lung cancer's share of all cancers in the United States — nobody calls that a rounding error. And the IARC number may be the low end: Moore suspects the estimate is conservative, and other analyses have put infection-linked cancers at 15 to 20 percent of global cases.

The math rests on IARC's GLOBOCAN database, the most up-to-date worldwide assessment of its kind, covering 36 cancer types in 2024. It's worth being honest about the foundation: the authors themselves note gaps in coverage and data quality in under-represented regions, which could push the true burden in either direction. But this is still the best global accounting we have, and it added 16 infection–cancer links that the previous 2018 estimate didn't include — cancers linked to HIV, to Merkel cell polyomavirus, and a longer list of cancer sites tied to hepatitis B and C, Kaposi sarcoma–associated herpesvirus, and Epstein–Barr virus.

The usual suspects, ranked

Four pathogens account for roughly 92 percent of the infection-driven cancers. Not exotic lab curiosities — things most of us have already heard of:

- Helicobacter pylori, the stomach bacterium, led the count with about 760,000 cases — mostly gastric cancers, driven by long-term inflammation of the stomach lining. Half the world carries H. pylori; most carriers never get cancer. But at population scale, that chronic irritation adds up to the single largest slice. - Human papillomavirus (HPV) was close behind at around 750,000 cases. Every cervical cancer — about 600,000 cases — is attributed to HPV, plus a share of anal, vulvar, vaginal, penile, and head-and-neck cancers. HPV works with particular nastiness: its proteins disable the cell's tumor-suppressor machinery, the emergency brakes that would normally force a damaged cell to die. - Hepatitis B (360,000 cases) causes roughly half of all hepatocellular carcinoma, the most common liver cancer, mostly through decades of chronic liver damage and cirrhosis. - Epstein–Barr virus (EBV) (260,000 cases) — the same virus behind mononucleosis — is now the fourth-leading infectious cause of cancer worldwide, ahead of hepatitis C. It transforms B cells in ways that can lead to lymphoma, and it's behind 88 percent of nasopharyngeal cancer. - Hepatitis C added another 160,000 cases, mostly liver.

The geography is strikingly uneven, and it reads like a map of global inequity. Eastern Asia carried 42 percent of the world total — 990,000 cases — driven by H. pylori and hepatitis B, with Mongolia, Japan, and South Korea showing especially high H. pylori–linked rates. Southeast Asia's share of cancers from infections was 16 percent, above the 12 percent global average, with EBV-linked nasopharyngeal cancer disproportionately common. Sub-Saharan Africa carries the HPV burden hardest.

The common mechanism, as IARC scientists describe it, is unsettling in its intimacy: these pathogens hijack the machinery that controls the normal cell cycle to fuel their own replication, knocking out the repair systems that would otherwise fix mutated genes or order damaged cells to self-destruct. Chronic inflammation and repeated tissue damage do the rest. For at least five of the major agents, the pathogen even carries its own oncogenes — cancer-causing genes — that can trigger cancer directly when inserted into healthy cells.

The prevention gap isn't a science problem

Here's the part that stings. Unlike the cancers driven by genetics or aging, infection-driven cancers are, as the researchers put it, particularly amenable to prevention. We already have the tools: vaccines against HPV and hepatitis B, effective treatment for H. pylori, hepatitis B and C, and HIV, cervical and anal lesion screening, safe injection practices. Hepatitis C — a virus that caused 160,000 cancers in 2024 — can now be cured with a short course of antivirals.

The glaring exception is Epstein–Barr virus, for which no vaccine exists. The authors single that gap out as a case for investing in new prevention tools, and it matters most in places like Southeast Asia, where EBV-linked nasopharyngeal cancer is common.

So why are 2.3 million people still getting these cancers? The study points at the usual suspects — and none of them are scientific. Limited access to vaccination and screening. Stigma around HPV and HIV that keeps people from seeking care. Political will that never materialized. And a warning worth underlining: Dr. Moore cautioned that cutbacks in HIV treatment following the disbanding of USAID could drive more infection-linked cancers in sub-Saharan Africa, where the burden is already heaviest. The tools exist; the delivery systems keep failing.

What this changes — and what it doesn't

A reasonable objection: does this underplay the genes-and-lifestyle story? No. Smoking, alcohol, and inherited risk still matter enormously. What the IARC study does is add a third pillar that's been under-counted and under-discussed — and the crucial difference is actionability. You can't edit your genome. You can, very often, get a vaccine, take a course of antibiotics, or get screened.

And the practical takeaway is refreshingly concrete. If you haven't been vaccinated against HPV, that's the single highest-leverage cancer-prevention act most adults can take. Hepatitis B vaccination is close behind. H. pylori testing and treatment — a breath or stool test and a round of antibiotics — wipes out the bacterium behind 760,000 cancers a year. Cervical cancer screening reaches the cancers we already know how to catch early. For men, HPV vaccination and awareness remain dramatically under-promoted; the virus doesn't care about your gender.

Cancer will always feel like a roll of the dice. This study says that for one in eight patients, the dice were loaded by something treatable — and we chose, mostly by inaction, not to unload them. That's the uncomfortable number to sit with. The recognition is growing. What happens next is a matter of delivery, not discovery.

References

• Recatools — "Infections Caused 2.3 Million Cancers in 2024, IARC Finds" (Oct 1, 2026): https://recatools.com/news/infection-attributable-cancer-2024-iarc-lancet-oncology-southeast-asia/
• Medscape — "Nearly 1 in 8 Cancers Worldwide Caused by Infections" (2026): https://www.medscape.com/viewarticle/nearly-1-8-cancers-worldwide-caused-infections-2026a10010mx
• BullSource — "1 in 8 Cancer Cases Worldwide Linked to Infections, Study Finds" (with Newsweek expert interviews): https://bullsource.com/news/1-in-8-cancer-cases-worldwide-linked-to-infections-study-finds/
• Times Now — "1 In 8 New Cancers May Be Caused By Infections" (Sep 29, 2026): https://www.timesnownews.com/health/1-in-8-new-cancers-may-be-caused-by-infections-article-156244718
• Primary study: IARC analysis published in The Lancet Oncology, October 2026 issue (GLOBOCAN 2024 data)